Brandon BioCatalyst, a collaboration of more than 50 of Australia and New Zealand’s leading medical research institutes, hospitals and universities, has announced new board appointments to continue the scaling of Australian medical research into globally competitive biotech companies. He understood deeply that successful biotech companies not only deliver investor returns but also generate high-value jobs and improved health outcomes,” said Dr Chris Nave, Brandon BioCatalyst CEO and Brandon Capital Managing Partner. Beattie is a long-time champion of innovation, biotech and medical research, having developed and championed the Queensland Smart State strategy that set up the Medical Research Institutes which delivered Gardasil and, more recently, Vicebio. Beattie said he will continue to advance Ferris’s strategic vision, ensuring Brandon BioCatalyst remains focused on translating biotech research into commercial outcomes and building globally competitive biotech companies, while delivering programs and capital that unlock research potential. “As Chair of Brandon BioCatalyst, I’m focused on ensuring Australia’s biotech innovations are equipped with the capital, capabilities and connections needed to retain lasting value in Australia,” Beattie said.